Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:ponatinib
go back to main search page
Accession:CHEBI:78543 term browser browse the term
Definition:A benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABL(T315I).
Synonyms:exact_synonym: 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
 related_synonym: AP 24534;   AP24534;   Formula=C29H27F3N6O;   InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39);   InChIKey=PHXJVRSECIGDHY-UHFFFAOYSA-N;   SMILES=CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1;   ponatinibum
 xref: CAS:943319-70-8;   DrugBank:DB08901;   Drug_Central:4716;   HMDB:HMDB0240214;   KEGG:D09950;   LINCS:LSM-1151
 xref_mesh: MESH:C545373
 xref: PMCID:PMC8895737;   PMID:24297701;   PMID:24402926;   PMID:24407160;   PMID:24408322;   PMID:24472312;   PMID:24481648;   PMID:24550512;   PMID:24552773;   PMID:24586514;   PMID:24596204;   PMID:24602068;   PMID:24695735;   PMID:24729118;   PMID:24756787;   PMID:24766374;   PMID:24768818;   PMID:24807266;   PMID:24934866;   PMID:30417093;   PMID:33929369;   PMID:34406581;   PMID:34649276;   PMID:34821935;   PMID:34871094;   PMID:34885009;   PMID:34939982;   PMID:34984405;   PMID:34987886;   PMID:35059859;   PMID:35091442;   PMID:35091541;   PMID:35122387;   PMID:35151199;   PMID:35325305;   PMID:35332794;   PMID:35338182;   PMID:35349077;   PMID:35411096;   PMID:35412404;   PMID:35544670;   Patent:US2014038920;   Reaxys:12923700;   Wikipedia:Ponatinib
 cyclic_relationship: is_conjugate_base_of CHEBI:191939


show annotations for term's descendants           Sort by:
ponatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions
decreases activity
decreases phosphorylation 		ISO ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of ABL1 protein mutant form]; ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; ponatinib inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein]
ponatinib analog results in decreased activity of ABL1 protein; ponatinib analog results in decreased activity of ABL1 protein mutant form; ponatinib results in decreased activity of ABL1 protein; ponatinib results in decreased activity of ABL1 protein mutant form
ponatinib results in decreased phosphorylation of ABL1 protein; ponatinib results in decreased phosphorylation of ABL1 protein mutant form 		CTD PMID:19878872 PMID:20513156 PMID:21561767 PMID:22781593 PMID:25304212 NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:14,979,853...15,083,065 		JBrowse link
G Abl2 ABL proto-oncogene 2, non-receptor tyrosine kinase decreases activity ISO ponatinib results in decreased activity of ABL2 protein CTD PMID:19878872 NCBI chr13:71,223,902...71,319,770
Ensembl chr13:68,673,722...68,839,742 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of AKT1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of AKT1 protein] CTD PMID:25053825 PMID:25304212 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions 		ISO ponatinib results in increased expression of BAX mRNA
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of BAX mRNA] 		CTD PMID:34699866 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of BCL2 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of BCL2 protein]
ponatinib results in decreased expression of BCL2 mRNA
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of BCL2 mRNA]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of BCL2 mRNA] 		CTD PMID:25053825 PMID:34699866 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of BCL2L11 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] CTD PMID:25053825 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases phosphorylation ISO ponatinib results in decreased phosphorylation of BCR protein mutant form CTD PMID:19878872 NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,471,668...13,597,016 		JBrowse link
G Blk BLK proto-oncogene, Src family tyrosine kinase decreases activity ISO ponatinib results in decreased activity of BLK protein CTD PMID:19878872 NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031 		JBrowse link
G Bmx BMX non-receptor tyrosine kinase decreases activity ISO ponatinib results in decreased activity of BMX protein CTD PMID:19878872 NCBI chr  X:30,227,251...30,290,015
Ensembl chr  X:30,227,251...30,289,993 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase decreases activity ISO ponatinib analog results in decreased activity of BRAF protein; ponatinib analog results in decreased activity of BRAF protein mutant form CTD PMID:21561767 NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:68,384,649...68,510,463 		JBrowse link
G Casp1 caspase 1 increases expression
multiple interactions 		ISO ponatinib results in increased expression of CASP1 mRNA
Acetylcysteine inhibits the reaction [ponatinib results in increased activity of CASP1 protein]; Acetylcysteine inhibits the reaction [ponatinib results in increased expression of CASP1 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased activity of and results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of CASP1 mRNA]; ponatinib results in increased activity of and results in increased cleavage of CASP1 protein 		CTD PMID:39134127 NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp3 caspase 3 increases cleavage ISO ponatinib results in increased cleavage of CASP3 protein CTD PMID:29341879 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression 		ISO [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of CASP9 protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of CASP9 protein] CTD PMID:34699866 Ensembl chr 5:154,109,046...154,126,626 JBrowse link
G Cat catalase multiple interactions
increases activity 		ISO [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased activity of CAT protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased activity of CAT protein] CTD PMID:34699866 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions
decreases expression 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of CDK4 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK4 protein] CTD PMID:25053825 NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of CDK6 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK6 protein] CTD PMID:25053825 NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in increased expression of CDKN1A protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein] CTD PMID:25053825 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions
decreases phosphorylation 		ISO ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]
ponatinib results in decreased phosphorylation of CRKL protein 		CTD PMID:19878872 PMID:25304212 NCBI chr11:97,033,033...97,067,457
Ensembl chr11:83,526,530...83,563,238 		JBrowse link
G Csf1r colony stimulating factor 1 receptor decreases activity ISO ponatinib analog results in decreased activity of CSF1R protein; ponatinib results in decreased activity of CSF1R protein CTD PMID:19878872 PMID:21561767 NCBI chr18:56,834,152...56,860,804
Ensembl chr18:54,546,659...54,590,415 		JBrowse link
G Csk C-terminal Src kinase decreases activity ISO ponatinib results in decreased activity of CSK protein CTD PMID:19878872 NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:58,029,749...58,048,292 		JBrowse link
G Ddr1 discoidin domain receptor tyrosine kinase 1 decreases phosphorylation ISO ponatinib inhibits the reaction [collagen increases autophosphorylation of DDR1 in U2OS cells] RGD PMID:24768818 RGD:151347549 NCBI chr20:3,047,269...3,069,277
Ensembl chr20:3,044,320...3,064,468 		JBrowse link
G Ddr2 discoidin domain receptor tyrosine kinase 2 decreases activity ISO ponatinib results in decreased activity of DDR2 protein CTD PMID:19878872 NCBI chr13:84,726,412...84,851,032
Ensembl chr13:82,195,463...82,317,363 		JBrowse link
G Egfr epidermal growth factor receptor decreases activity ISO ponatinib results in decreased activity of EGFR protein mutant form CTD PMID:19878872 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Epha1 Eph receptor A1 decreases activity ISO ponatinib results in decreased activity of EPHA1 protein CTD PMID:19878872 NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846 		JBrowse link
G Epha2 Eph receptor A2 decreases activity ISO ponatinib analog results in decreased activity of EPHA2 protein; ponatinib results in decreased activity of EPHA2 protein CTD PMID:19878872 PMID:21561767 NCBI chr 5:158,888,629...158,917,100
Ensembl chr 5:153,605,644...153,634,117 		JBrowse link
G Epha3 Eph receptor A3 decreases activity ISO ponatinib analog results in decreased activity of EPHA3 protein; ponatinib results in decreased activity of EPHA3 protein CTD PMID:19878872 PMID:21561767 NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900 		JBrowse link
G Epha4 Eph receptor A4 decreases activity ISO ponatinib results in decreased activity of EPHA4 protein CTD PMID:19878872 NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:78,815,460...78,958,139 		JBrowse link
G Epha5 EPH receptor A5 decreases activity ISO ponatinib results in decreased activity of EPHA5 protein CTD PMID:19878872 NCBI chr14:23,653,393...24,020,129
Ensembl chr14:23,653,393...24,017,317 		JBrowse link
G Epha7 Eph receptor A7 decreases activity ISO ponatinib analog results in decreased activity of EPHA7 protein; ponatinib results in decreased activity of EPHA7 protein CTD PMID:19878872 PMID:21561767 NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112 		JBrowse link
G Epha8 Eph receptor A8 decreases activity ISO ponatinib results in decreased activity of EPHA8 protein CTD PMID:19878872 NCBI chr 5:154,449,566...154,476,966
Ensembl chr 5:149,166,697...149,193,399 		JBrowse link
G Ephb1 Eph receptor B1 decreases activity ISO ponatinib results in decreased activity of EPHB1 protein CTD PMID:19878872 NCBI chr 8:102,507,549...102,944,839
Ensembl chr 8:102,507,549...102,944,839 		JBrowse link
G Ephb2 Eph receptor B2 decreases activity ISO ponatinib results in decreased activity of EPHB2 protein CTD PMID:19878872 NCBI chr 5:154,179,065...154,360,459
Ensembl chr 5:148,897,246...149,077,059 		JBrowse link
G Ephb3 Eph receptor B3 decreases activity ISO ponatinib results in decreased activity of EPHB3 protein CTD PMID:19878872 NCBI chr11:79,840,668...79,859,345
Ensembl chr11:79,840,668...79,859,370 		JBrowse link
G Ephb4 EPH receptor B4 decreases activity ISO ponatinib results in decreased activity of EPHB4 protein CTD PMID:19878872 NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314 		JBrowse link
G Erbb4 erb-b2 receptor tyrosine kinase 4 decreases activity ISO ponatinib results in decreased activity of ERBB4 protein CTD PMID:19878872 NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595 		JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 decreases activity
decreases phosphorylation 		ISO ponatinib analog results in decreased activity of FGFR1 protein; ponatinib results in decreased activity of FGFR1 protein; ponatinib results in decreased activity of FGFR1 protein mutant form
ponatinib results in decreased phosphorylation of FGFR1 protein mutant form 		CTD PMID:19878872 PMID:21482694 PMID:21561767 PMID:22875613 NCBI chr16:73,194,631...73,249,855
Ensembl chr16:66,494,042...66,547,350 		JBrowse link
G Fgfr2 fibroblast growth factor receptor 2 decreases activity ISO ponatinib analog results in decreased activity of FGFR2 protein; ponatinib results in decreased activity of FGFR2 protein; ponatinib results in decreased activity of FGFR2 protein mutant form CTD PMID:19878872 PMID:21561767 NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:184,745,420...184,850,626 		JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 decreases activity ISO ponatinib analog results in decreased activity of FGFR3 protein; ponatinib results in decreased activity of FGFR3 protein CTD PMID:19878872 PMID:21561767 NCBI chr14:81,211,800...81,227,215
Ensembl chr14:76,987,993...77,003,341 		JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 decreases activity
multiple interactions
decreases expression 		ISO ponatinib analog results in decreased activity of FGFR4 protein; ponatinib results in decreased activity of FGFR4 protein
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of FGFR4 mRNA]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of FGFR4 mRNA] 		CTD PMID:19878872 PMID:21561767 PMID:34699866 NCBI chr17:9,466,686...9,481,423
Ensembl chr17:9,461,547...9,476,242 		JBrowse link
G Fgr FGR proto-oncogene, Src family tyrosine kinase decreases activity ISO ponatinib results in decreased activity of FGR protein CTD PMID:19878872 NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326 		JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 decreases activity ISO ponatinib analog results in decreased activity of FLT1 protein; ponatinib results in decreased activity of FLT1 protein CTD PMID:19878872 PMID:21561767 NCBI chr12:12,333,050...12,504,750
Ensembl chr12:7,297,292...7,468,626 		JBrowse link
G Flt3 Fms related receptor tyrosine kinase 3 decreases activity
multiple interactions
decreases phosphorylation 		ISO ponatinib analog results in decreased activity of FLT3 protein; ponatinib results in decreased activity of FLT3 protein; ponatinib results in decreased activity of FLT3 protein mutant form
ponatinib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form]
ponatinib results in decreased phosphorylation of FLT3 protein mutant form 		CTD PMID:19878872 PMID:21482694 PMID:21561767 PMID:22409268 NCBI chr12:12,660,035...12,735,584
Ensembl chr12:7,623,930...7,699,474 		JBrowse link
G Flt4 Fms related receptor tyrosine kinase 4 decreases activity ISO ponatinib analog results in decreased activity of FLT4 protein; ponatinib results in decreased activity of FLT4 protein CTD PMID:19878872 PMID:21561767 NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770 		JBrowse link
G Frk fyn-related Src family tyrosine kinase decreases activity ISO ponatinib results in decreased activity of FRK protein CTD PMID:19878872 NCBI chr20:38,265,416...38,371,038
Ensembl chr20:38,265,280...38,371,114 		JBrowse link
G Fyn FYN proto-oncogene, Src family tyrosine kinase decreases activity ISO ponatinib results in decreased activity of FYN protein CTD PMID:19878872 NCBI chr20:44,322,635...44,514,498
Ensembl chr20:42,766,369...42,959,911 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO ponatinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsdmd gasdermin D multiple interactions
increases expression 		ISO N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of GSDMD protein]
ponatinib results in increased expression of GSDMD mRNA; ponatinib results in increased expression of GSDMD protein 		CTD PMID:39134127 NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055 		JBrowse link
G Hck HCK proto-oncogene, Src family tyrosine kinase decreases activity ISO ponatinib results in decreased activity of HCK protein CTD PMID:19878872 NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:141,571,587...141,614,693 		JBrowse link
G Il1b interleukin 1 beta increases secretion
multiple interactions 		ISO ponatinib results in increased secretion of IL1B protein
Acetylcysteine inhibits the reaction [ponatinib results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased secretion of IL1B protein] 		CTD PMID:39134127 NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Jak1 Janus kinase 1 decreases activity ISO ponatinib results in decreased activity of JAK1 protein CTD PMID:19878872 NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:115,780,248...115,888,926 		JBrowse link
G Jak2 Janus kinase 2 decreases activity ISO ponatinib results in decreased activity of JAK2 protein CTD PMID:19878872 NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Jak3 Janus kinase 3 decreases activity ISO ponatinib results in decreased activity of JAK3 protein CTD PMID:19878872 NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,386,405...18,398,536 		JBrowse link
G Kdr kinase insert domain receptor decreases activity ISO ponatinib analog results in decreased activity of KDR protein; ponatinib results in decreased activity of KDR protein CTD PMID:19878872 PMID:21561767 NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases activity
decreases phosphorylation 		ISO ponatinib results in decreased activity of KIT protein; ponatinib results in decreased activity of KIT protein mutant form
ponatinib results in decreased phosphorylation of KIT protein mutant form 		CTD PMID:19878872 PMID:21482694 NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,548,877...32,624,652 		JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase decreases activity ISO ponatinib results in decreased activity of LCK protein CTD PMID:19878872 NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:141,888,326...141,903,794 		JBrowse link
G Lmna lamin A/C increases cleavage ISO ponatinib results in increased cleavage of LMNA protein CTD PMID:22875613 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423 		JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase decreases activity ISO ponatinib results in decreased activity of LYN protein CTD PMID:19878872 NCBI chr 5:21,437,127...21,553,097
Ensembl chr 5:16,639,466...16,756,868 		JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha increases lipidation ISO ponatinib results in increased lipidation of MAP1LC3A protein CTD PMID:29341879 NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of MAPK1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK1 protein] CTD PMID:22409268 PMID:22875613 PMID:25053825 PMID:25304212 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in decreased phosphorylation of MAPK3 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK3 protein] CTD PMID:22409268 PMID:22875613 PMID:25053825 PMID:25304212 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression ISO ponatinib results in decreased expression of MCL1 protein CTD PMID:22409268 NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in decreased expression of MYC protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein] CTD PMID:25053825 NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 increases expression
multiple interactions 		ISO ponatinib results in increased expression of NLRP3 mRNA; ponatinib results in increased expression of NLRP3 protein
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ponatinib results in increased expression of NLRP3 protein] 		CTD PMID:39134127 NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Ntrk1 neurotrophic receptor tyrosine kinase 1 decreases activity ISO ponatinib results in decreased activity of NTRK1 protein CTD PMID:19878872 NCBI chr 2:175,534,844...175,551,664
Ensembl chr 2:173,236,963...173,253,770 		JBrowse link
G Ntrk2 neurotrophic receptor tyrosine kinase 2 decreases activity ISO ponatinib results in decreased activity of NTRK2 protein CTD PMID:19878872 NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,559,043...5,869,136 		JBrowse link
G Ntrk3 neurotrophic receptor tyrosine kinase 3 decreases activity ISO ponatinib results in decreased activity of NTRK3 protein CTD PMID:19878872 NCBI chr 1:141,526,192...141,913,575
Ensembl chr 1:132,132,849...132,503,286 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage 		ISO (+)-JQ1 compound promotes the reaction [ponatinib results in increased cleavage of PARP1 protein]; ponatinib promotes the reaction [(+)-JQ1 compound results in increased cleavage of PARP1 protein] CTD PMID:21482694 PMID:22875613 PMID:25053825 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pdgfra platelet derived growth factor receptor alpha decreases activity
decreases phosphorylation 		ISO ponatinib analog results in decreased activity of PDGFRA protein; ponatinib results in decreased activity of PDGFRA protein; ponatinib results in decreased activity of PDGFRA protein mutant form
ponatinib results in decreased phosphorylation of PDGFRA protein mutant form 		CTD PMID:19878872 PMID:21482694 PMID:21561767 NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,005,839...33,054,335 		JBrowse link
G Pdgfrb platelet derived growth factor receptor beta decreases activity ISO ponatinib analog results in decreased activity of PDGFRB protein; ponatinib results in decreased activity of PDGFRB protein CTD PMID:19878872 PMID:21561767 NCBI chr18:56,770,348...56,809,228
Ensembl chr18:54,499,964...54,538,843 		JBrowse link
G Ptk2b protein tyrosine kinase 2 beta decreases activity ISO ponatinib results in decreased activity of PTK2B protein CTD PMID:19878872 NCBI chr15:44,536,275...44,656,754
Ensembl chr15:40,360,723...40,481,282 		JBrowse link
G Ptk6 protein tyrosine kinase 6 decreases activity ISO ponatinib results in decreased activity of PTK6 protein CTD PMID:19878872 NCBI chr 3:168,307,073...168,315,664
Ensembl chr 3:168,307,073...168,315,664 		JBrowse link
G Ret ret proto-oncogene decreases activity ISO ponatinib analog results in decreased activity of RET protein; ponatinib results in decreased activity of RET protein; ponatinib results in decreased activity of RET protein mutant form CTD PMID:19878872 PMID:21561767 NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase decreases activity ISO ponatinib analog results in decreased activity of SRC protein; ponatinib results in decreased activity of SRC protein CTD PMID:19878872 PMID:21561767 NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Stat5a signal transducer and activator of transcription 5A multiple interactions
decreases phosphorylation 		ISO ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5A protein]
ponatinib results in decreased phosphorylation of STAT5A protein 		CTD PMID:22875613 PMID:25053825 NCBI chr10:86,285,859...86,310,187
Ensembl chr10:85,785,537...85,809,866 		JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions ISO ponatinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5B protein] CTD PMID:25053825 NCBI chr10:86,205,148...86,276,178
Ensembl chr10:85,705,670...85,775,668 		JBrowse link
G Tek TEK receptor tyrosine kinase decreases activity ISO ponatinib analog results in decreased activity of TEK protein; ponatinib results in decreased activity of TEK protein CTD PMID:19878872 PMID:21561767 NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:109,607,077...109,733,804 		JBrowse link
G Tnni3 troponin I3, cardiac type increases secretion ISO ponatinib results in increased secretion of TNNI3 protein CTD PMID:25304212 NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression 		ISO [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of TRP53 protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of TRP53 protein] CTD PMID:34699866 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Tyk2 tyrosine kinase 2 decreases activity ISO ponatinib results in decreased activity of TYK2 protein CTD PMID:19878872 NCBI chr 8:27,918,054...27,943,319
Ensembl chr 8:19,641,884...19,667,044 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 decreases activity ISO ponatinib results in decreased activity of UGT1A1 protein CTD PMID:37597759 NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 decreases activity ISO ponatinib results in decreased activity of UGT1A9 protein CTD PMID:37597759 NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression 		ISO [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of VEGFA protein]; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of VEGFA protein] CTD PMID:34699866 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Yes1 YES proto-oncogene 1, Src family tyrosine kinase decreases activity ISO ponatinib results in decreased activity of YES1 protein CTD PMID:19878872 NCBI chr 9:113,200,256...113,275,942
Ensembl chr 9:113,200,256...113,299,837 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20856
    role 20816
      application 20617
        pharmaceutical 20413
          drug 20413
            antineoplastic agent 18066
              ponatinib 83
Path 2
Term Annotations click to browse term
  CHEBI ontology 20856
    subatomic particle 20854
      composite particle 20854
        hadron 20854
          baryon 20854
            nucleon 20854
              atomic nucleus 20854
                atom 20854
                  main group element atom 20777
                    p-block element atom 20777
                      carbon group element atom 20710
                        carbon atom 20704
                          organic molecular entity 20704
                            heteroorganic entity 20215
                              organochalcogen compound 19902
                                organooxygen compound 19804
                                  carbon oxoacid 19150
                                    carboxylic acid 19147
                                      carboacyl group 18082
                                        univalent carboacyl group 18082
                                          carbamoyl group 17918
                                            carboxamide 17918
                                              monocarboxylic acid amide 15949
                                                arenecarboxamide 8283
                                                  benzamides 8283
                                                    ponatinib 83
paths to the root